Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Anti-NY ESO-1 mTCR PBL|
|Synonyms||NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|
Anti-NY ESO-1 mTCR PBL are peripheral blood lymphocytes that have been transduced with a retroviral vector expressing a T-cell receptor that targets NY-ESO, which may enhance anti-tumor immune response against NY-ESO-expressing tumor cells (PMID: 24598449).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine||Aldesleukin Anti-NY ESO-1 mTCR PBL Cyclophosphamide Fludarabine||0||1|
|Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine + NY-ESO-1 peptide vaccine||Aldesleukin Anti-NY ESO-1 mTCR PBL Cyclophosphamide Fludarabine NY-ESO-1 peptide vaccine||0||1|
|Anti-NY ESO-1 mTCR PBL||Anti-NY ESO-1 mTCR PBL||0||0|
|Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + TGFbDNRII-transduced autologous TILs||Anti-NY ESO-1 mTCR PBL Cyclophosphamide TGFbDNRII-transduced autologous TILs||0||1|